PATENT CLAIM ANALYSIS

Application Number: 16128892
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-05
Patent Classification: ["514", "374000"]

Abstract:
The present invention relates to the use of aleglitazar in the treatment or prevention of diabetic kidney disease in a patient having a linear decline in GFR.

Claim (Index 8):
The method of  claim 7 , wherein the aleglitazar is orally administered at a dose of 150 ug once a day.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 97.0
- Lexical Diversity: 1.21739
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15616974', '14928048', '14918727', '15918401', '15354053']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6430021525648378
- 35 USC 102 Novelty (BERT): 0.4876131418106308
- Combined Prediction Score: 0.6274632514894172
- Mean Citation Score: 126.92687199999996
- Max Citation Score: 141.80608
- Similarity Product: 96.11108115051267

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test